Chuangyebang was informed that Enkaisai Pharmaceutical (Shanghai Enkai Cell Technology Co., Ltd.) recently announced the completion of a series A financing of more than 100 million yuan. This round of financing was led by Huagai Capital, Chinese Academy of Sciences Venture Capital, Gandao Fund, Chengyi Capital, and Sirius Capital. , Qiao Jing Capital and others followed suit. The funds raised in this round will be used for the research and development of a series of NK cell drug product pipelines at various stages.
Formed by the core technical team led by Academician Tian Zhigang, Enkasai Pharmaceuticals focuses on the transformation and development of innovative cell drug technology based on NK cells, and is committed to providing more effective and safe precise immunotherapy methods for the majority of patients. In March 2020, with the strong support of the Shanghai Municipal Government, Zhangjiang Management Committee and Zhangjiang Group, Enkasai settled in Zhangjiang Cell Industrial Park.
Tian Zhigang, the founder of the company, is a banner figure in the field of immunology in China, an academician of the Chinese Academy of Engineering, and one of the 16 executive committee members of the International Federation of Immunology. Academician of the European Academy of Sciences, becoming a dual academician.
The co-founder of the company, Professor Xiao Weihua, worked at the Changchun Institute of Biological Products in the 1980s, and then studied and worked at Johns Hopkins, the Cancer Research Center of the University of Maryland, and the National Cancer Institute for more than 10 years. Professor of the School of Life Sciences, Director of the Biomedical Engineering Technology Research Center of the University of Science and Technology of China.
Using synthetic immunology technologies such as logic loops, feedback switches, and intelligent control, Nkasai Pharmaceuticals quantifies, controllable, and intelligently quantifies NK cell drugs through gene manipulation, so as to artificially create NK cells that meet different clinical needs, which will help tumors. It brings new hope to patients with many other diseases, and will become a model for my country’s independent intellectual property rights of cell-based drugs to go to the world.
With the blessing of this round of financing, Enkaise Pharmaceuticals will continue to innovate, continuously enrich product pipelines, develop core technologies, and absorb more international high-end talents from the industry to enrich the team.
Academician Tian Zhigang, founder of Enkasai, said: “Immune cell drugs are the third era of biomedicine after small molecule drugs and macromolecular protein and nucleic acid drugs. Due to the unprecedented ‘living drug’ properties of cell-based drugs, they are endowed with unprecedented Prospects for development. NK cells are the “Natural Killer cells (NK cells)” of tumors, viruses, and senescent cells, which will greatly make up for the insufficiency of CAR-T cell therapy and greatly break through the ceiling of CAR-T cell therapy.
Co-founder Xiao Weihua said: “Enkaise Pharmaceutical is a technology transformation company established with more than 30 years of accumulation. It has completely independent innovation and distinctive technology and genetically modified pipeline products, and will become the source and leader of immune cell drug innovation. Industrial development biotech company.”
Zhang Yi, managing partner of Huagai Medical’s early stage fund, said: “We continue to be optimistic about innovative technology platforms in the field of cell therapy. NK cell therapy is a track that our team has been researching and paying attention to. The potential of large-scale clinical application. We are very happy to lead Enkai in this round, and we are optimistic that Enkai will become the leading NK cell therapy company in China and even in the world. Enkai will work together to benefit the vast number of cancer patients around the world.”
media coverage
The investment community invests in China Net Ventures, Bang Yiou
Related events
- Enkasai Pharma received more than 100 million yuan in Series A financing led by Huagai Capital2022-07-01
- Spectrum Biotech completes tens of millions of Pre-A+ rounds of financing in the short term2022-06-17
- Elite completed the A round of financing of over 100 million yuan, led by Zhengxingu Capital2022-05-13
- Xinchuan Bio completed nearly 100 million yuan in seed round financing2022-03-28
- Spectrum Biotech completed nearly 100 million yuan of Pre-A round of financing2022-03-17
This article is reprinted from: https://readhub.cn/topic/8hhSsQuQmiU
This site is for inclusion only, and the copyright belongs to the original author.